Ocular Therapeutix Inc (OCUL)
NASDAQ:OCUL
Want to see OCUL full AI Analyst Report?
OCUL Stock Chart & Stats
$9.82
-$0.16(-1.76%)
At close: 4:00 PM EST
$9.82
-$0.16(-1.76%)
Day’s Range― - ―
52-Week Range$6.23 - $16.44
Previous CloseN/A
Volume219.73K
Average Volume (3M)2.85M
Market Cap
$2.21B
Enterprise Value$1.52B
Total Cash (Recent Filing)$666.70M
Total Debt (Recent Filing)$79.46M
Price to Earnings (P/E)―
Beta1.37
Next Earnings
Aug 10, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.46
Shares Outstanding218,960,360
10 Day Avg. Volume3,172,143
30 Day Avg. Volume2,848,330
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)3.47
Price to Sales (P/S)43.86
P/FCF Ratio-10.48
Enterprise Value/Market Cap0.69
Enterprise Value/Revenue29.28
Enterprise Value/Gross Profit33.56
Enterprise Value/Ebitda-5.56
Forecast
1Y Price Target
$25.50Price Target Upside159.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.6
Revenue Forecast (FY)$51.89M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsProduct-level economics show very high gross margins, indicating strong pricing power and low direct COGS for the DEXTENZA platform. Durable margin structure can fund R&D and commercialization investment, and provides room to absorb SG&A while scaling revenue.
Low Financial LeverageRelatively low leverage gives the company financing flexibility through a cash runway or access to debt markets without high interest burden. This structural balance sheet strength reduces default risk and supports execution of regulatory and launch activities over the next 2–6 months.
FDA-aligned NDA Path For AXPAXLIManagement secured FDA alignment to pursue an NDA for AXPAXLI (wet AMD) and is streamlining registrational plans, a structural de-risking step. A clear regulatory path materially increases the probability of a transformative product approval and future revenue streams.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow shows the business currently cannot self-fund operations or pivotal regulatory work. Over months this creates reliance on external financing, which can dilute shareholders or constrain investment pacing for launches and trials.
Very Large Operating LossesExtremely negative margins reflect operating costs far exceeding current revenue. Without material commercial uplift or approval-driven revenue, persistent losses will erode equity and require repeated financing, making profitability a multi-quarter structural challenge.
Equity Plan Expansion / Dilution RiskAuthorizing 10 million additional equity awards and issuing executive equity ties compensation to stock but increases potential dilution over time. This can pressure per-share metrics and long-term returns if financing needs persist or awards are used to conserve cash.
Ocular Therapeutix News
OCUL FAQ
What was Ocular Therapeutix Inc’s price range in the past 12 months?
Ocular Therapeutix Inc lowest stock price was $6.23 and its highest was $16.44 in the past 12 months.
What is Ocular Therapeutix Inc’s market cap?
Ocular Therapeutix Inc’s market cap is $2.21B.
When is Ocular Therapeutix Inc’s upcoming earnings report date?
Ocular Therapeutix Inc’s upcoming earnings report date is Aug 10, 2026 which is in 46 days.
How were Ocular Therapeutix Inc’s earnings last quarter?
Ocular Therapeutix Inc released its earnings results on May 05, 2026. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.315 by -$0.085.
Is Ocular Therapeutix Inc overvalued?
According to Wall Street analysts Ocular Therapeutix Inc’s price is currently Undervalued.
Does Ocular Therapeutix Inc pay dividends?
Ocular Therapeutix Inc does not currently pay dividends.
What is Ocular Therapeutix Inc’s EPS estimate?
Ocular Therapeutix Inc’s EPS estimate is -0.4.
How many shares outstanding does Ocular Therapeutix Inc have?
Ocular Therapeutix Inc has 218,960,360 shares outstanding.
What happened to Ocular Therapeutix Inc’s price movement after its last earnings report?
Ocular Therapeutix Inc reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.315. Following the earnings report the stock price went down -0.614%.
Which hedge fund is a major shareholder of Ocular Therapeutix Inc?
Currently, no hedge funds are holding shares in OCUL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ocular Therapeutix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$25.50 (159.67% Upside)
$25.50 (159.67% Upside)
Blogger Sentiment
Bullish
OCUL Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 31.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $360.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 0.6%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
20.84%
12-Months-Change
Fundamentals
Return on Equity
-64.55%
Trailing 12-Months
Asset Growth
80.46%
Trailing 12-Months
Company Description
Ocular Therapeutix Inc
Ocular Therapeutix, Inc. is a biopharmaceutical company specializing in the creation, advancement, and commercialization of ophthalmic treatments. Their innovative approach leverages a proprietary bioresorbable hydrogel technology to address a range of eye diseases and conditions. The company currently offers two key products: ReSure Sealant, an ophthalmic device designed to prevent fluid leakage from corneal incisions after cataract surgery, and DEXTENZA, a dexamethasone-based ophthalmic insert used to manage post-surgical inflammation and pain in the eye, as well as to treat allergic conjunctivitis. In addition to their commercial offerings, Ocular Therapeutix is actively developing several product candidates in various clinical stages, including: OTX-TKI, an axitinib intravitreal implant in Phase 1 clinical trials for wet age-related macular degeneration (AMD) and other retinal diseases. OTX-TIC, a travoprost intracameral implant, currently in Phase 2 studies for open-angle glaucoma and ocular hypertension. OTX-CSI, a cyclosporine intracanalicular insert that has successfully completed Phase 2 clinical trials for dry eye disease. OTX-DED, a dexamethasone intracanalicular insert undergoing Phase 2 evaluation for the temporary relief of dry eye symptoms. Strategic partnerships are also a significant part of Ocular Therapeutix's operations. This includes a collaboration with Regeneron Pharmaceuticals, Inc. focused on developing and commercializing products that combine Ocular Therapeutix's sustained-release hydrogel technology with Regeneron's large molecule VEGF-targeting compounds for retinal disease treatment. Another partnership with AffaMed Therapeutics Limited covers the development and commercialization of DEXTENZA and OTX-TIC. Additionally, a discovery-focused collaboration with Mosaic Biosciences aims to pinpoint novel targets and therapeutic agents for dry age-related macular degeneration (dAMD). Established in 2006, Ocular Therapeutix, Inc. maintains its headquarters in Bedford, Massachusetts.
OCUL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and financial stability, with strong support from payers and successful trial execution. However, challenges such as market pricing pressure and potential enrollment difficulties in diabetic retinopathy trials were noted.View all OCUL earnings summariesOCUL Stock 12 Month Forecast
Average Price Target
$25.50
▲(159.67% Upside)
Technical Analysis
―
Beam Therapeutics
―
Tarsus Pharmaceuticals
―
ARS Pharmaceuticals
―
Belite Bio, Inc. ADR
―
Ownership Overview
2.72% Insiders
20.34% Mutual Funds
40.35% Other Institutional Investors
26.31% Public Companies and Individual Investors